1. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation
- Author
-
Kathryn A. Gold, Adam S. Garden, Abdallah S.R. Mohamed, Jayashree Kalpathy-Cramer, Brian Pham, Hillary Eichelberger, Tommy Sheu, Merrill S. Kies, Michael H. Kroll, C. French, Jack Phan, David I. Rosenthal, Stephen Y. Lai, Sara Shoultz-Henley, Clifton D. Fuller, Erich M. Sturgis, Blaine D. Smith, G. Brandon Gunn, Zeina Ayoub, and Amos J. Hayes
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Complete blood count ,Cancer ,Phlebotomy ,Nomogram ,medicine.disease ,Surgery ,Radiation therapy ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oropharyngeal Neoplasm ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Platelet ,business ,Chemoradiotherapy - Abstract
The purpose of this study is to evaluate potential associations between increased platelets and oncologic outcomes in oropharyngeal cancer patients receiving concurrent chemoradiation. A total of 433 oropharyngeal cancer patients (OPC) treated with intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy between 2002 and 2012 were included under an approved IRB protocol. Complete blood count (CBC) data were extracted. Platelet and hemoglobin from the last phlebotomy (PLTpre-chemoRT, Hgbpre-chemoRT ) before start of treatment were identified. Patients were risk-stratified using Dahlstrom-Sturgis criteria and were tested for association with survival and disease-control outcomes. Locoregional control (LRC), freedom from distant metastasis (FDM) and overall survival (OS) were decreased (p
- Published
- 2015